Randomized trial shows semaglutide results in significant weight loss in older adults — Evidence Review
Published by researchers at University of Padova, Novo Nordisk
Researched by
— the AI search engine for science
Table of Contents
Adults over 65 with obesity achieved significant and sustained weight loss using semaglutide, as shown in a new University of Padova analysis; these results align with previous studies across age groups and support semaglutide’s effectiveness and safety profile in older populations. Broader research similarly finds semaglutide effective for weight and cardiometabolic risk reduction, with manageable side effects, though questions remain about long-term adherence and the importance of lifestyle interventions.
- Multiple studies have consistently demonstrated semaglutide’s efficacy in producing clinically meaningful weight loss and improving metabolic health in both diabetic and non-diabetic adults, with effects sustained over time while on treatment 2 6 7 9 12.
- The current findings in older adults agree with meta-analyses and real-world studies showing similar weight loss and glycemic control across age groups, although some highlight that weight loss may need to be balanced against frailty risks in the elderly 4 6 9.
- Research also emphasizes that while semaglutide is generally well-tolerated, gastrointestinal side effects are common, and discontinuation can result in rapid weight regain, underscoring the need for ongoing patient monitoring and combined lifestyle interventions 1 5 12.
Study Overview and Key Findings
Obesity in older adults presents unique challenges, including increased comorbidities and frailty, potentially complicating pharmacological interventions. Despite the widespread use of GLP-1 receptor agonists like semaglutide for weight loss, there has been limited data specifically focused on the efficacy and safety of these drugs in individuals over 65. This analysis, pooling data from several STEP clinical trials, provides new insight into semaglutide's impact in this age group, addressing an important evidence gap at a time when obesity rates are rising among older adults.
| Property | Value |
|---|---|
| Organization | University of Padova, Novo Nordisk |
| Authors | Prof. Luca Busetto, colleagues from Novo Nordisk |
| Population | Adults over 65 with obesity |
| Sample Size | n=358 |
| Methods | Randomized Controlled Trial (RCT) |
| Outcome | Weight loss, waist circumference, cardiometabolic risk factors |
| Results | Semaglutide led to 15.4% weight loss vs 5.1% with placebo |
The study analyzed data from multiple STEP trials, focusing on 358 participants aged 65 and older with overweight or obesity but without diabetes. Participants received either semaglutide 2.4 mg weekly or placebo, alongside lifestyle counseling. Over 68 weeks, semaglutide recipients lost an average of 15.4% of their body weight, compared to 5.1% in the placebo group. Improvements were also observed in waist circumference and cardiometabolic risk factors, such as blood pressure, blood lipids, and glycated hemoglobin. The safety profile was similar to that seen in younger adults, with gastrointestinal side effects like constipation and dizziness being the most common. Serious adverse events were somewhat more frequent in the semaglutide group (19.0% vs 12.7%), but rates of fractures and hypoglycemia remained low (<1%).
Literature Review: Related Studies
To contextualize these findings, we searched the Consensus research database using the following queries:
- Ozempic weight loss elderly population
- semaglutide obesity treatment outcomes
- placebo weight loss comparison elderly
Below, we organize the literature into key topics and summarize the main findings as they relate to the new study.
| Topic | Key Findings |
|---|---|
| How effective is semaglutide for weight loss in older adults and other populations? | - Semaglutide produces substantial and sustained weight loss across diverse age groups, including older adults, with similar efficacy in real-world and clinical trial settings 4 6 9 12. - Weight loss is typically greater in non-diabetic versus diabetic populations 6 8. |
| What are the effects of semaglutide on cardiometabolic health? | - Semaglutide improves glycemic control, blood pressure, and lipid profiles in obese and diabetic patients, and reduces cardiovascular event risk in high-risk populations 1 2 7. - Benefits persist with continued treatment; discontinuation often leads to weight regain 7 12. |
| What are the safety concerns and side effects of semaglutide? | - Gastrointestinal side effects (nausea, constipation, diarrhea) are most common, but generally manageable; serious adverse events are rare, though higher in semaglutide compared to placebo 1 5 6 9. - Discontinuation rates due to side effects vary, and weight regain is common 5 12. |
| How do perceptions and societal factors influence semaglutide use? | - Use of semaglutide is sometimes perceived as a shortcut, with less praiseworthiness compared to traditional weight loss methods, and there are concerns about non-medical use and sustainability of weight loss without lifestyle changes 3 5. |
How effective is semaglutide for weight loss in older adults and other populations?
The new study’s findings are consistent with a broad body of evidence indicating that semaglutide leads to marked weight loss in both older and younger adults. Meta-analyses and real-world audits have shown that the magnitude of weight reduction is similar regardless of age, although baseline body weight may differ. Clinical trials in non-diabetic populations report even greater relative weight loss, emphasizing semaglutide’s efficacy as part of a comprehensive obesity management strategy.
- Both clinical trials and real-world audits report substantial weight reduction with semaglutide across age groups, including those over 65 4 6 9.
- Weight loss is generally greater in non-diabetic populations compared to those with diabetes 6 8.
- The STEP trials, including long-term studies, confirm sustained weight loss while treatment is maintained 6 9 12.
- The findings support semaglutide as an option for obesity management in older adults, with efficacy comparable to younger cohorts 4 6.
What are the effects of semaglutide on cardiometabolic health?
Improvements in weight are accompanied by positive changes in cardiometabolic risk factors. Several studies show semaglutide reduces glycated hemoglobin (HbA1c), blood pressure, and lipid levels, and can decrease the risk of major cardiovascular events in at-risk populations. These effects are evident in both diabetic and non-diabetic individuals, and benefits are generally sustained as long as treatment continues.
- Semaglutide improves glycemic control and reduces cardiometabolic risk factors in overweight/obese adults 1 2 7.
- The SELECT trial found lower rates of cardiovascular events with semaglutide compared to placebo in high-risk, non-diabetic patients 7.
- Weight loss and metabolic improvements are generally greater with semaglutide than with other anti-obesity medications 2.
- Cardiometabolic benefits diminish if treatment is discontinued, highlighting the need for ongoing therapy 7 12.
What are the safety concerns and side effects of semaglutide?
Gastrointestinal symptoms are the most frequently reported adverse effects of semaglutide, but are usually mild to moderate and transient. Serious adverse events are rare but slightly more common than with placebo. Discontinuation due to AEs occurs in a minority of patients, but cessation often leads to weight regain and reversal of metabolic gains. The safety profile is similar across age groups, though clinicians should monitor older adults for frailty and other age-related vulnerabilities.
- Gastrointestinal side effects are common but typically manageable, occurring in both older and younger adults 1 5 6 9.
- Serious adverse events are infrequent, but more common with semaglutide than placebo 5 6 9.
- Discontinuing semaglutide often leads to rapid weight regain and loss of cardiometabolic improvements 5 12.
- Safety and tolerability in older adults are broadly similar to the general population, though individualized assessment is advised 4 6 9.
How do perceptions and societal factors influence semaglutide use?
Public and professional attitudes toward semaglutide use can affect patient acceptance and adherence. Some view medication-assisted weight loss as less praiseworthy than traditional methods, and there are concerns about the use of semaglutide for purely aesthetic reasons or in populations without clinical obesity. These factors may influence patient counseling, adherence, and regulatory policy.
- Weight loss achieved with semaglutide is often perceived as less effortful and less praiseworthy than weight loss through diet and exercise alone 3.
- Non-medical and aesthetic use of semaglutide raises ethical and public health concerns, including drug shortages and the risk of inappropriate prescribing 5.
- Effective obesity management should include lifestyle interventions alongside pharmacotherapy 1 5.
- Patient education and regulation are essential to ensure safe and appropriate use, especially as demand increases 5.
Future Research Questions
While the current study provides important evidence for semaglutide’s use in older adults with obesity, several questions remain. Future research should investigate the long-term safety and effectiveness of semaglutide in diverse older populations, optimal management strategies to prevent frailty, and the psychosocial impacts of medication-assisted weight loss. Understanding individual factors that predict response and adherence, as well as the effects of discontinuation, will further inform clinical practice.
| Research Question | Relevance |
|---|---|
| What are the long-term safety and efficacy outcomes of semaglutide in adults over 65? | Long-term data specific to older adults are limited; understanding sustained effects and risks is crucial for this growing population 4 6 9. |
| How does semaglutide treatment affect frailty, muscle mass, and physical function in elderly patients? | Weight loss in older adults may risk increasing frailty or reducing muscle mass; studies should clarify these outcomes and guide safe prescribing 4 5. |
| What predicts adherence and treatment persistence with semaglutide in older adults? | Adherence is challenged by side effects and perceptions of medication; identifying predictors will help optimize outcomes 1 3 5. |
| Does combining semaglutide with structured lifestyle interventions improve long-term outcomes in older adults with obesity? | Lifestyle interventions are a critical component of weight management; research should test the best strategies for integration with pharmacotherapy 1 5 8. |
| What are the psychosocial impacts of medication-assisted weight loss in the elderly? | Understanding the emotional, cognitive, and social effects of weight loss medications can inform patient counseling and improve quality of life 3. |
This comprehensive evidence base demonstrates that semaglutide is a promising option for managing obesity in older adults, with benefits for weight loss and cardiometabolic health. Ongoing research is needed to address long-term outcomes, optimize treatment strategies, and ensure safe, effective care for this vulnerable population.